Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.56 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856729 | 0.85 | SRC (0.56) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| Cyclohexylamine SCHEMBL7792578 | 0.85 | ADAMTS5 (0.47) | ADAMTS5KMOALDH1A1NPC1RAB9A | |
| SCHEMBL30631693 | 0.85 | SRC (0.60) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL6849018 | 0.85 | SRC (0.60) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL11217503 | 0.84 | HPGD (0.55) | ADAMTS5ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL30715071 | 0.84 | HPGD (0.55) | ADAMTS5ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL415226 | 0.84 | HPGD (0.55) | ADAMTS5ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL31287758 | 0.84 | ALDH1A1 (0.61) | ADAMTS5KMOALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL894981 | 0.84 | ALDH1A1 (0.61) | ADAMTS5KMOALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6852137 | 0.83 | SRC (0.58) | ALDH1A1NPC1RAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230271950-A1 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4171221-A2 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | University of Notre Dame du Lac (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2022005976-A2 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3303333-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2019-11-20 | — | — | EP | disclosed |
| EP-2794620-B1 | BODIPY STRUCTURE FLUORESCENCE PROBES FOR DIVERSE BIOLOGICAL APPLICATIONS | NAT UNIV SINGAPORE (SG) | 2017-11-15 | — | — | EP | disclosed |
| WO-2017106552-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AND COMBINATION THERAPY | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106552-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AND COMBINATION THERAPY | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-0595995-B1 | ARYLAMIDOALKYL- AND ARYLAMINOALKYL-N-HYDROXYUREA COMPOUNDS AND -N-HYDROXYFORMAMIDE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996034851-A1 | BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5514702-A | Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995032184-A1 | SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE- BASED MOLECULES HAVING AT LEAST TWO STRUCTURAL DIVERSITY ELEMENTS | ARQULE, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| EP-0595995-A4 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0595995-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5214204-A | Inhibitors of biosynthesis of leukotrienes | ABBOTT LABORATORIES (US) | 1993-05-25 | — | — | US | disclosed |
| WO-1993002037-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1993-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | ADAMTS5 2684/4885KMO 1038/4885ALDH1A1 2743/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | ADAMTS5 2684/4885KMO 1038/4885ALDH1A1 2743/4885 |
| US-20230271950-A1 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | RPL35, RPL5, RPL23 | ADAMTS5 3870/4885KMO 1882/4885ALDH1A1 3518/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | ADAMTS5 2422/4885KMO 1126/4885ALDH1A1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.